Vanda Pharmaceuticals Inc. VNDA

VNDA Company Overview

Vanda Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapies for central nervous system disorders, sleep-related conditions, inflammatory diseases, and rare disorders. The company operates within the biotechnology and specialty pharmaceutical industries and generates revenue primarily from sales of approved prescription products and, to a lesser extent, licensing and collaboration arrangements. Its commercial portfolio has centered on therapies targeting neurological and psychiatric conditions, including circadian rhythm sleep disorders and schizophrenia-related indications.

The company’s principal marketed products include HETLIOZ® (tasimelteon), approved for non-24-hour sleep-wake disorder and certain circadian rhythm disorders, and Fanapt® (iloperidone), an antipsychotic approved for schizophrenia and bipolar disorder-related indications in the United States. Vanda has also advanced a pipeline spanning gastroenterology, neurology, ophthalmology, and immunology. Founded in 2002 and headquartered in Washington, D.C., the company evolved from a development-stage biotechnology firm into a commercial-stage pharmaceutical company following U.S. regulatory approvals and subsequent commercialization efforts. Public filings and investor materials consistently identify the company’s strategy as combining internally developed therapies with targeted lifecycle management and selective acquisition opportunities.